• Tablets: 150 mg, scored (3) • Tablets: 300 mg (3) • Oral Solution: 10 mg per mL (3) CONTRAINDICATIONS -----to lamivudine
การรักษาลมพิษ
The effect of food on the rate and extent of absorption was also studied
The tablets are white to off-white colored, capsule shaped, bevelled edged, biconvex, film-coated, debossed with “I” on one side and “47” on other side
If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an The recommended dosage of lamivudine tablets in HIV-1-infected adults is 300 mg daily, administered as either 150 mg taken orally twice daily or 300 mg taken orally once daily with or without food
( 2
Close follow-up for a few months is needed when therapy is stopped in people who have hepatitis B
• EPIVIR Oral Solution
It is available as tablets (150 and 300 mg) and as an oral solution (10 mg/ml)
100 mg once daily, patients receiving lamivudine for concomitant HIV infection should continue to COMBIVIR Tablets, containing 150 mg lamivudine and 300 mg zidovudine, are white, scored, film-coated, modified-capsule-shaped tablets, debossed on both tablet faces, such that when broken in half, the full “GXFC3” code is present on both halves of the tablet (“GX” on one face and “FC3” on the opposite face of the tablet)
Subscription required to view
Each scored 150-mg film-coated tablet contains 150 mg of lamivudine and the inactive ingredients hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide
Use: In combination with other antiretrovirals, for the treatment of HIV-1 infection
Generic: lamivudine 150 mg and zidovudine 300 mg